The Effect of Acetazolamide on Saccadic Latency at 3459 Meters Olivia K. Faull, BS, BPhEd, Josephine Robertson, BA, Owen Thomas, BMedSci, MBChB, Arthur R. Bradwell, FRCP, Chrystalina A. Antoniades, PhD, Kyle T.S. Pattinson, DPhil, FRCA  Wilderness & Environmental Medicine  Volume 26, Issue 1, Pages 72-77 (March 2015) DOI: 10.1016/j.wem.2014.08.017 Copyright © 2015 Wilderness Medical Society Terms and Conditions

Figure 1 Median (± interquartile range) measurements at baseline (sea level) and altitude (3459 m) for the placebo (Pl) group (n = 10 [black lines]) and for the group taking 250 mg acetazolamide (Az) every 12 hours (n = 9 [gray lines]). (A) Prosaccadic latencies: comparisons between baseline and altitude within each group, placebo (P = .19) and acetazolamide (P = .008); there were no statistical differences between groups (P = .14 baseline; P = .6 altitude). (B) Antisaccadic latencies: there were no statistically significant differences (P > .05) between groups and from baseline to altitude. (C) Oxygen saturations: a significant difference (P = .001) existed between groups at altitude. Wilderness & Environmental Medicine 2015 26, 72-77DOI: (10.1016/j.wem.2014.08.017) Copyright © 2015 Wilderness Medical Society Terms and Conditions

Figure 2 Saccadometer headpiece (oculometer), worn across the bridge of the nose and against the forehead. The headpiece contains 3 lasers to project either a central fixation point or a visual target to the left or right of the central fixation, to which the participants were instructed to make a saccade. Wilderness & Environmental Medicine 2015 26, 72-77DOI: (10.1016/j.wem.2014.08.017) Copyright © 2015 Wilderness Medical Society Terms and Conditions